AMBASSADOR Trial: Adjuvant pembrolizumab improved disease-free survival in high-risk muscle-invasive urothelial carcinoma post-surgery (29.6 vs 14.2 months; HR 0.73). Grade ≥3 AEs: 50.6%.
@nejm.org @oncoalert.bsky.social @erplimackmd.bsky.social
@drchoueiri.bsky.social
@oncbrothers.bsky.social